BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Irukayama-Tomobe Y, Ogawa Y, Tominaga H, Ishikawa Y, Hosokawa N, Ambai S, Kawabe Y, Uchida S, Nakajima R, Saitoh T, Kanda T, Vogt K, Sakurai T, Nagase H, Yanagisawa M. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci U S A 2017;114:5731-6. [PMID: 28507129 DOI: 10.1073/pnas.1700499114] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
Number Citing Articles
1 Calva CB, Fadel JR. Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction. Brain Res 2020;1731:145921. [PMID: 30148983 DOI: 10.1016/j.brainres.2018.08.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
2 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
3 Kulkarni K, Schow M, Shubrook JH. Shift Workers at Risk for Metabolic Syndrome. J Am Osteopath Assoc 2020;120:107-17. [PMID: 31985761 DOI: 10.7556/jaoa.2020.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Zhou W, Cheung K, Kyu S, Wang L, Guan Z, Kurien PA, Bickler PE, Jan LY. Activation of orexin system facilitates anesthesia emergence and pain control. Proc Natl Acad Sci U S A 2018;115:E10740-7. [PMID: 30348769 DOI: 10.1073/pnas.1808622115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
5 Takahashi T, Noriaki S, Matsumura M, Li C, Takahashi K, Nishino S. Advances in pharmaceutical treatment options for narcolepsy. Expert Opinion on Orphan Drugs 2018;6:597-610. [DOI: 10.1080/21678707.2018.1521267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Szabo ST, Thorpy MJ, Mayer G, Peever JH, Kilduff TS. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy. Sleep Med Rev 2019;43:23-36. [PMID: 30503715 DOI: 10.1016/j.smrv.2018.09.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
7 Bassetti CLA, Adamantidis A, Burdakov D, Han F, Gay S, Kallweit U, Khatami R, Koning F, Kornum BR, Lammers GJ, Liblau RS, Luppi PH, Mayer G, Pollmächer T, Sakurai T, Sallusto F, Scammell TE, Tafti M, Dauvilliers Y. Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol 2019;15:519-39. [DOI: 10.1038/s41582-019-0226-9] [Cited by in Crossref: 113] [Cited by in F6Publishing: 89] [Article Influence: 37.7] [Reference Citation Analysis]
8 Hong C, Byrne NJ, Zamlynny B, Tummala S, Xiao L, Shipman JM, Partridge AT, Minnick C, Breslin MJ, Rudd MT, Stachel SJ, Rada VL, Kern JC, Armacost KA, Hollingsworth SA, O'Brien JA, Hall DL, McDonald TP, Strickland C, Brooun A, Soisson SM, Hollenstein K. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation. Nat Commun 2021;12:815. [PMID: 33547286 DOI: 10.1038/s41467-021-21087-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
9 Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S. An overview of hypocretin based therapy in narcolepsy. Expert Opinion on Investigational Drugs 2018;27:389-406. [DOI: 10.1080/13543784.2018.1459561] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
10 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
11 Kaushik MK, Aritake K, Imanishi A, Kanbayashi T, Ichikawa T, Shimizu T, Urade Y, Yanagisawa M. Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy. Proc Natl Acad Sci U S A 2018;115:6046-51. [PMID: 29784823 DOI: 10.1073/pnas.1722686115] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
12 Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci 2019;20:83-93. [PMID: 30546103 DOI: 10.1038/s41583-018-0097-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 18.7] [Reference Citation Analysis]
13 Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV. Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2019;10:709. [PMID: 31695678 DOI: 10.3389/fendo.2019.00709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
14 Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord 2019;12:1756286419875622. [PMID: 31632459 DOI: 10.1177/1756286419875622] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
15 Demidova A, Kahl E, Fendt M. Orexin deficiency affects sensorimotor gating and its amphetamine-induced impairment. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2022. [DOI: 10.1016/j.pnpbp.2022.110517] [Reference Citation Analysis]
16 Vringer M, Kornum BR. Emerging therapeutic targets for narcolepsy. Expert Opin Ther Targets 2021;:1-14. [PMID: 34402358 DOI: 10.1080/14728222.2021.1969361] [Reference Citation Analysis]
17 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
18 Miyagawa T, Tanaka S, Shimada M, Sakai N, Tanida K, Kotorii N, Kotorii T, Ariyoshi Y, Hashizume Y, Ogi K, Hiejima H, Kanbayashi T, Imanishi A, Ikegami A, Kamei Y, Hida A, Wada Y, Miyamoto M, Takami M, Kondo H, Tamura Y, Taniyama Y, Omata N, Mizuno T, Moriya S, Furuya H, Kato M, Kato K, Ishigooka J, Tsuruta K, Chiba S, Yamada N, Okawa M, Hirata K, Kuroda K, Kume K, Uchimura N, Kitada M, Kodama T, Inoue Y, Nishino S, Mishima K, Tokunaga K, Honda M. A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia. NPJ Genom Med 2022;7:29. [PMID: 35414074 DOI: 10.1038/s41525-022-00298-w] [Reference Citation Analysis]
19 Couvineau A, Dayot S, Nicole P, Gratio V, Rebours V, Couvelard A, Voisin T. The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. Front Endocrinol (Lausanne) 2018;9:573. [PMID: 30319552 DOI: 10.3389/fendo.2018.00573] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
20 Jaggard JB, Stahl BA, Lloyd E, Prober DA, Duboue ER, Keene AC. Hypocretin underlies the evolution of sleep loss in the Mexican cavefish. Elife 2018;7:e32637. [PMID: 29405117 DOI: 10.7554/eLife.32637] [Cited by in Crossref: 52] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
21 Tang H, Zhu Q, Li W, Qin S, Gong Y, Wang H, Shioda S, Li S, Huang J, Liu B, Fang Y, Liu Y, Wang S, Guo Y, Xia Q, Guo Y, Xu Z. Neurophysiology and Treatment of Disorders of Consciousness Induced by Traumatic Brain Injury: Orexin Signaling as a Potential Therapeutic Target. Curr Pharm Des 2019;25:4208-20. [PMID: 31663471 DOI: 10.2174/1381612825666191029101830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Barateau L, Liblau R, Peyron C, Dauvilliers Y. Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment. CNS Drugs 2017;31:821-34. [DOI: 10.1007/s40263-017-0464-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
23 Iio K, Saitoh T, Ohshita R, Hino T, Amezawa M, Takayama Y, Nagumo Y, Yamamoto N, Kutsumura N, Irukayama-tomobe Y, Ishikawa Y, Tanimura R, Yanagisawa M, Nagase H. Discovery of Orexin 2 Receptor Selective and Dual Orexin Receptor Agonists based on the Tetralin Structure: Switching of Receptor Selectivity by Chirality on the Tetralin Ring. Bioorganic & Medicinal Chemistry Letters 2022. [DOI: 10.1016/j.bmcl.2022.128555] [Reference Citation Analysis]
24 Nirogi R, Benade V, Daripelli S, Subramanian R, Kamuju V, Bhyrapuneni G, Muddana NR, Mekala VR, Petlu S, Jayarajan P, Badange R, Shinde A, Jasti V. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation. Psychopharmacology (Berl) 2021;238:1495-511. [PMID: 33550481 DOI: 10.1007/s00213-021-05779-x] [Reference Citation Analysis]
25 Ohrui S, Yamamoto N, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, Part II: Drastic effect of the 14-hydroxy group on the orexin 1 receptor antagonistic activity. Bioorganic & Medicinal Chemistry Letters 2018;28:774-7. [DOI: 10.1016/j.bmcl.2017.12.069] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
26 Bian H, Huang L, Li B, Hu Q, Liang X, Tang J, Zhang JH. The arousal effect of hyperbaric oxygen through orexin/hypocretin an upregulation on ketamine/ethanol-induced unconsciousness in male rats. J Neurosci Res 2020;98:201-11. [PMID: 30895638 DOI: 10.1002/jnr.24414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Calva CB, Fayyaz H, Fadel JR. Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats. Front Aging Neurosci 2019;11:362. [PMID: 32038222 DOI: 10.3389/fnagi.2019.00362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Yukitake H, Fujimoto T, Ishikawa T, Suzuki A, Shimizu Y, Rikimaru K, Ito M, Suzuki M, Kimura H. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice. Pharmacology Biochemistry and Behavior 2019;187:172794. [DOI: 10.1016/j.pbb.2019.172794] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
29 Giblin KA, Basili D, Afzal AM, Rosenbrier-Ribeiro L, Greene N, Barrett I, Hughes SJ, Bender A. New Associations between Drug-Induced Adverse Events in Animal Models and Humans Reveal Novel Candidate Safety Targets. Chem Res Toxicol 2021;34:438-51. [PMID: 33338378 DOI: 10.1021/acs.chemrestox.0c00311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Beuckmann CT, Ueno T, Nakagawa M, Suzuki M, Akasofu S. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep 2019;42:zsz076. [PMID: 30923834 DOI: 10.1093/sleep/zsz076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
31 Toyama S, Shimoyama N, Tagaito Y, Nagase H, Saitoh T, Yanagisawa M, Shimoyama M. Nonpeptide Orexin-2 Receptor Agonist Attenuates Morphine-induced Sedative Effects in Rats. Anesthesiology 2018;128:992-1003. [PMID: 29521652 DOI: 10.1097/ALN.0000000000002161] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
32 Turku A, Leino TO, Karhu L, Yli-Kauhaluoma J, Kukkonen JP, Wallén EAA, Xhaard H. Structure-Activity Relationships of 1-Benzoylazulenes at the OX1 and OX2 Orexin Receptors. ChemMedChem 2019;14:965-81. [PMID: 30892823 DOI: 10.1002/cmdc.201900074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Zhang D, Perrey DA, Decker AM, Langston TL, Mavanji V, Harris DL, Kotz CM, Zhang Y. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists. J Med Chem 2021;64:8806-25. [PMID: 34101446 DOI: 10.1021/acs.jmedchem.1c00841] [Reference Citation Analysis]
34 Wang Q, Cao F, Wu Y. Orexinergic System in Neurodegenerative Diseases. Front Aging Neurosci 2021;13:713201. [PMID: 34483883 DOI: 10.3389/fnagi.2021.713201] [Reference Citation Analysis]
35 Seigneur E, de Lecea L. Hypocretin (Orexin) Replacement Therapies. Medicine in Drug Discovery 2020;8:100070. [DOI: 10.1016/j.medidd.2020.100070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Yamamoto N, Ohrui S, Okada T, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, part III: Role of the 14-hydroxy and the 3-methoxy groups in antagonistic activity toward the orexin 1 receptor in YNT-707 derivatives lacking the 4,5-epoxy ring. Bioorganic & Medicinal Chemistry 2019;27:1747-58. [DOI: 10.1016/j.bmc.2019.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
37 Hino T, Saitoh T, Nagumo Y, Yamamoto N, Kutsumura N, Irukayama-Tomobe Y, Ishikawa Y, Tanimura R, Yanagisawa M, Nagase H. Design and synthesis of novel orexin 2 receptor agonists based on naphthalene skeleton. Bioorg Med Chem Lett 2022;:128530. [PMID: 35007725 DOI: 10.1016/j.bmcl.2022.128530] [Reference Citation Analysis]
38 Li SB, de Lecea L. The hypocretin (orexin) system: from a neural circuitry perspective. Neuropharmacology 2020;167:107993. [PMID: 32135427 DOI: 10.1016/j.neuropharm.2020.107993] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
39 Ohsawa M, Makino T, Takimoto Y, Inui A. Application of Kampo medicines for the palliation of cancer cachexia. Neuropeptides 2021;90:102188. [PMID: 34488048 DOI: 10.1016/j.npep.2021.102188] [Reference Citation Analysis]
40 Sahni AS, Carlucci M, Malik M, Prasad B. Management Of Excessive Sleepiness In Patients With Narcolepsy And OSA: Current Challenges And Future Prospects. Nat Sci Sleep 2019;11:241-52. [PMID: 31695533 DOI: 10.2147/NSS.S218402] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Janockova J, Dolezal R, Nepovimova E, Kobrlova T, Benkova M, Kuca K, Konecny J, Mezeiova E, Melikova M, Hepnarova V, Ring A, Soukup O, Korabecny J. Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods. Molecules 2018;23:E2926. [PMID: 30423961 DOI: 10.3390/molecules23112926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Reading PJ. Update on narcolepsy. J Neurol 2019;266:1809-15. [DOI: 10.1007/s00415-019-09310-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
44 Boss C, Gatfield J, Brotschi C, Heidmann B, Sifferlen T, von Raumer M, Schmidt G, Williams JT, Treiber A, Roch C. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders. ChemMedChem 2020;15:2286-305. [PMID: 32937014 DOI: 10.1002/cmdc.202000453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Liguori G, Tafuri S, Miyoshi C, Yanagisawa M, Squillacioti C, De Pasquale V, Mirabella N, Vittoria A, Costagliola A. Localization of orexin B and orexin-2 receptor in the rat epididymis. Acta Histochem 2018;120:292-7. [PMID: 29496265 DOI: 10.1016/j.acthis.2018.02.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
46 Equihua-Benítez AC, Equihua-Benítez JA, Guzmán-Vásquez K, Prospero-García O, Drucker-Colín R. Orexin cell transplant reduces behavioral arrest severity in narcoleptic mice. Brain Res 2020;1745:146951. [PMID: 32531224 DOI: 10.1016/j.brainres.2020.146951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Nemoto T, Irukayama-Tomobe Y, Hirose Y, Tanaka H, Takahashi G, Takahashi S, Yanagisawa M, Kanbayashi T. Effect of sevoflurane preconditioning on sleep reintegration after alteration by lipopolysaccharide. J Sleep Res 2022;:e13556. [PMID: 35170121 DOI: 10.1111/jsr.13556] [Reference Citation Analysis]
48 Yamamoto K, Okui R, Yamatodani A. Activation of orexinergic and histaminergic pathway involved in therapeutic effect of histamine H4 receptor antagonist against cisplatin-induced anorexia in mice. Naunyn Schmiedebergs Arch Pharmacol 2019;392:925-36. [PMID: 30919010 DOI: 10.1007/s00210-019-01646-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med 2020;68:97-109. [PMID: 32032921 DOI: 10.1016/j.sleep.2019.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
50 Nepovimova E, Janockova J, Misik J, Kubik S, Stuchlik A, Vales K, Korabecny J, Mezeiova E, Dolezal R, Soukup O, Kobrlova T, Pham NL, Nguyen TD, Konecny J, Kuca K. Orexin supplementation in narcolepsy treatment: A review. Med Res Rev 2019;39:961-75. [PMID: 30426515 DOI: 10.1002/med.21550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
51 Kaushik MK, Aritake K, Cherasse Y, Imanishi A, Kanbayashi T, Urade Y, Yanagisawa M. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice. Sleep 2021:zsab043. [PMID: 33609365 DOI: 10.1093/sleep/zsab043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Tsuneki H, Wada T, Sasaoka T. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders. Pharmacology & Therapeutics 2018;186:25-44. [DOI: 10.1016/j.pharmthera.2017.12.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
53 Rinne MK, Leino TO, Turku A, Turunen PM, Steynen Y, Xhaard H, Wallén EA, Kukkonen JP. Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26. European Journal of Pharmacology 2018;837:137-44. [DOI: 10.1016/j.ejphar.2018.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
54 Arrigoni E, Chee MJS, Fuller PM. To eat or to sleep: That is a lateral hypothalamic question. Neuropharmacology 2019;154:34-49. [PMID: 30503993 DOI: 10.1016/j.neuropharm.2018.11.017] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
55 Prober DA. Discovery of Hypocretin/Orexin Ushers in a New Era of Sleep Research. Trends Neurosci 2018;41:70-2. [PMID: 29405929 DOI: 10.1016/j.tins.2017.11.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]